Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Combination of an h3 antagonist/inverse agonist and an appetite suppressant

An appetite suppressant and antagonist technology, applied in drug combinations, medical preparations containing active ingredients, metabolic diseases, etc., can solve problems that are not clearly described

Inactive Publication Date: 2009-03-04
SCHERING AG
View PDF41 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0021] However, none of the aforementioned patents, published patent applications, or articles explicitly describe H 3 A combination of an antagonist / inverse agonist and an appetite suppressant selected from CB 1 Antagonists (such as rimonabant), sibutramine, phentermine, and topiramate

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Combination of an h3 antagonist/inverse agonist and an appetite suppressant
  • Combination of an h3 antagonist/inverse agonist and an appetite suppressant
  • Combination of an h3 antagonist/inverse agonist and an appetite suppressant

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0031] As used above and throughout this disclosure, the following terms, unless otherwise indicated, shall be understood to have the following meanings:

[0032] A "patient" is a human or non-human mammal. In one embodiment, the patient is a human. In another embodiment, the patient is a non-human mammal including, but not limited to, monkeys, dogs, baboons, rhesus monkeys, mice, rats, horses, cats, or rabbits. In another embodiment, the patient is a companion animal including, but not limited to, a dog, cat, rabbit, horse or ferret. In one embodiment, the patient is a dog. In another embodiment, the patient is a cat.

[0033] "Alkyl" means an aliphatic hydrocarbon group which may be straight or branched and comprising about 1 to about 20 carbon atoms in the chain. The alkyl group can have from about 1 to about 12 carbon atoms in the chain, and in another embodiment, the alkyl group can have from about 1 to about 6 carbon atoms in the chain. Branched means that one or mo...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to pharmaceutical compositions comprising therapeutic combinations comprising: one or more H3 antagonists / inverse agonists; one or more appetite suppressants selected from the group consisting of CBi antagonists / inverse agonists, sibutramine, phentermine and topiramate; and option one or more HMG-CoA reductase inhibitors. The invention also relates to medicaments and kits comprising the pharmaceutical compositions of the present invention, and methods of treating obesity, obesity related disorders and diabetes using the pharmaceutical compositions of the present invention.

Description

technical field [0001] The present invention relates to pharmaceutical compositions comprising a therapeutic combination comprising: one or more H 3 Antagonist / inverse agonist; one or more appetite suppressants selected from CB 1 Antagonists / inverse agonists, sibutramine, phentermine, and topiramat; and optionally one or more HMG-CoA reductase inhibitors. The present invention also relates to medicaments and kits comprising the pharmaceutical compositions of the present invention, and methods of using the pharmaceutical compositions of the present invention to treat obesity, obesity-related disorders, and diabetes. Background technique [0002] histamine receptor H 1 、H 2 、H 3 and H 4 Has been characterized by its pharmacological behavior. h 1 Receptors are those that mediate responses antagonized by commonly used antihistamines. h 1 Receptors are found, for example, in the ileum, skin and bronchial smooth muscle of humans and other mammals. Most notably H 2 The r...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61P3/04A61P3/10A61K45/06
CPCA61K45/06A61K31/00A61K31/496A61K31/423A61K31/4192A61K31/5377A61K31/4745A61K31/428A61K31/541A61K31/517A61K31/4184A61K31/4178A61P3/04A61P3/10A61P43/00A61K2300/00C07D401/14
Inventor M·凡希克J·J·华M·P·葛雷兹诺J·E·拉克威兹T·J·柯华斯基E·P·维尔崔K·D·麦可寇米克M·Y·柏林R·G·亚斯兰安
Owner SCHERING AG
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com